期刊文献+

SBRT与胸腔镜手术治疗早期非小细胞肺癌疗效比较

Comparison of the Efficacy of SBRT and Thoracoscope Surgery in the Treatement of Early Non-Small-Cell Lung Carcinoma
下载PDF
导出
摘要 目的:比较立体定向放射治疗(SBRT)与胸腔镜手术治疗早期非小细胞肺癌(NSCLC)疗效。方法:选择2015年1月至2018年12月在洛阳市第三人民医院治疗的早期NSCLC患者42例,随机分为两组,SBRT组(21例)采取SBRT,胸腔镜治疗组(21例)采取胸腔镜手术治疗,分析比较两组患者1、2、3年总生存率(OS)与无病生存率(DFS)。结果:SBRT组和胸腔镜治疗组1、2、3年OS和DFS比较,差异均无统计学意义(P>0.05)。结论:胸腔镜手术治疗和SBRT对早期NSCLC的临床疗效相当,通常情况下二者均可作为早期NSCLC的主要治疗手段。但对于患者不愿手术或有手术禁忌证,SBRT可作为首选治疗方法。 Objective To compare the curative effect of stereotactic body radiotherapy(SBRT)and thoracoscopy surgery on early non-small cell lung cancer(NSCLC).Methods 42 patients with early NSCLC treated in Luoyang Third People’s Hospital from January 2015 to December 2018 were selected.The patients were divided into two groups:SBRT group with 21 cases received SBRT,thoracoscopic surgery group wih 21 cases received thoracoscopic surgery therapy,and the 1.2.3-year overall survival rate(OS)and disease-free survival rate(DFS)were analyzed and evaluated between the two groups.Results There was no significant difference in OS and DFS between the SBRT group and the thoracoscopic surgery group(P>0.05).Conclusion Thoracoscopic surgery therapy and SBRT have similar clinical efficacy for early NSCLC,and both are usually the primary treatment for early NSCLC.However,SBRT can be used as the first choice for patients who are unwilling or contraindicated for surgery.
作者 王辉 刘建民 孙超 WANG Hui;LIU Jian-min;SUN Chao(Luoyang Third People's Hospital,Henan Luoyang 471000)
出处 《深圳中西医结合杂志》 2021年第24期92-94,共3页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词 非小细胞肺癌 立体定向放射治疗 胸腔镜手术 Non-small cell lung cancer Stereotactic body radiotherapy Thoracoscopic surgery
  • 相关文献

参考文献6

二级参考文献57

  • 1夏廷毅,李宏奇,王颖杰,李平,孙庆选,范乃斌,于勇.全身γ刀治疗不能手术Ⅰ和Ⅱ期非小细胞肺癌的临床结果[J].中华放射肿瘤学杂志,2007,16(2):91-97. 被引量:56
  • 2Riely GJ, Politi KA, Miller VA, et al. Update on epidermal groxah factor receptor ntations in non-small cell lung cancer [ J ], Clin Cancer Res, 2006, 12(24):7232-7241.
  • 3Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2) :198-203.
  • 4Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non- small-cell lung cancer [ J ]. J Clin Oncol, 2012, 30 ( 4 ) : 433 -440.
  • 5Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J]. J Thorac Oncol, 2014, 9(2):154-162.
  • 6Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[ J]. Nature, 2007, 448(7153) :561-566.
  • 7Zhang X, Zhang S, Yang X, et al. Fusion of EMLA and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression [J]. Mol Cancer, 2010, 9:188.
  • 8Zhang NN, Liu YT, Ma L, et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy[ J]. PLoS One, 2014, 9 ( 1 ) : e84501.
  • 9Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol, 2008, 26(15) :2442-2449.
  • 10Mitsudnmi T, Morita S, Yatabe Y, et al. Gefitlnib versus eisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WYrOG5405): an open label, randnmised phase 5 trial [ J ]. Lancet Oncol, 2010, 11 (2) : 121-128.

共引文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部